Key Points
- Insider sale: Camille Bedrosian sold 6,580 shares of Amylyx (NASDAQ:AMLX) on Dec. 1 at an average price of $14.35 for about $94,423, trimming her stake by 3.61% to 175,756 shares (~$2.52M); the trade was reported to the SEC.
- Analyst sentiment has turned more positive with multiple firms (Goldman Sachs, HC Wainwright, Citi, etc.) raising price targets into the $16–$20 range; consensus is a Moderate Buy with a $17.25 target.
- Stock snapshot: AMLX opened around $14.21 with a $1.56B market cap, 50-/200-day moving averages of $13.99/$9.99, a 52-week range of $2.60–$16.96, and roughly 95.8% institutional ownership.
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX - Get Free Report) insider Camille Bedrosian sold 6,580 shares of the business's stock in a transaction dated Monday, December 1st. The shares were sold at an average price of $14.35, for a total transaction of $94,423.00. Following the completion of the sale, the insider directly owned 175,756 shares of the company's stock, valued at approximately $2,522,098.60. This trade represents a 3.61% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.
Amylyx Pharmaceuticals Stock Performance
Amylyx Pharmaceuticals stock opened at $14.21 on Thursday. The company has a market capitalization of $1.56 billion, a PE ratio of -7.89 and a beta of -0.34. The company has a 50 day moving average price of $13.99 and a 200-day moving average price of $9.99. Amylyx Pharmaceuticals, Inc. has a fifty-two week low of $2.60 and a fifty-two week high of $16.96.
Amylyx Pharmaceuticals (NASDAQ:AMLX - Get Free Report) last announced its quarterly earnings data on Thursday, November 6th. The company reported ($0.37) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.43) by $0.06. On average, analysts forecast that Amylyx Pharmaceuticals, Inc. will post -2.2 earnings per share for the current year.
Analyst Ratings Changes
AMLX has been the topic of several research reports. The Goldman Sachs Group raised their price target on Amylyx Pharmaceuticals from $10.00 to $20.00 and gave the company a "buy" rating in a research note on Tuesday, September 16th. HC Wainwright raised their target price on shares of Amylyx Pharmaceuticals from $16.00 to $20.00 and gave the company a "buy" rating in a research report on Friday, November 7th. Lifesci Capital raised shares of Amylyx Pharmaceuticals to a "strong-buy" rating in a research report on Monday, October 27th. Citigroup lifted their price objective on shares of Amylyx Pharmaceuticals from $12.00 to $20.00 and gave the company a "buy" rating in a report on Friday, October 17th. Finally, Bank of America upped their target price on Amylyx Pharmaceuticals from $14.00 to $16.00 and gave the stock a "buy" rating in a report on Friday, October 3rd. Two analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat, Amylyx Pharmaceuticals presently has a consensus rating of "Moderate Buy" and a consensus price target of $17.25.
Read Our Latest Stock Report on AMLX
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently modified their holdings of the company. Aster Capital Management DIFC Ltd purchased a new position in Amylyx Pharmaceuticals in the third quarter worth $48,000. California State Teachers Retirement System acquired a new stake in shares of Amylyx Pharmaceuticals in the 2nd quarter worth $28,000. Ameritas Investment Partners Inc. purchased a new position in Amylyx Pharmaceuticals during the 2nd quarter worth $45,000. BNP Paribas Financial Markets increased its position in Amylyx Pharmaceuticals by 433.2% during the 2nd quarter. BNP Paribas Financial Markets now owns 7,267 shares of the company's stock valued at $47,000 after buying an additional 5,904 shares in the last quarter. Finally, Legal & General Group Plc acquired a new position in Amylyx Pharmaceuticals during the 2nd quarter valued at about $47,000. Hedge funds and other institutional investors own 95.84% of the company's stock.
Amylyx Pharmaceuticals Company Profile
(
Get Free Report)
Amylyx Pharmaceuticals, Inc, a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
